ReShape Lifesciences Inc. Common Stock
RSLS
RSLS was delisted on the 28th of December, 2018.
2 hedge funds and large institutions have $187K invested in ReShape Lifesciences Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 14 closing their positions.
23% more capital invested
Capital invested by funds: $152K → $187K (+$35K)
87% less funds holding
Funds holding: 15 → 2 (-13)
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.72M |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$101K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 3 |
VF
Virtu Financial
New York
|
-$8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$5K |
| 5 |
Two Sigma Investments
New York
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $187K | +$1.72M | +729,350 | +22,115% |
|
|
2
Renaissance Technologies
New York
| – | -$101K | -16,341 | Closed |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$9K | -1,391 | Closed |
|
|
VF
4
Virtu Financial
New York
| – | -$8K | -1,285 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$5K | -796 | Closed |
|
|
6
Two Sigma Investments
New York
| – | -$4K | -568 | Closed |
|
|
IBT
7
International Biotechnology Trust
London,
United Kingdom
| – | -$2K | -375 | Closed |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$2K | -260 | Closed |
|
9
Vanguard Group
Malvern,
Pennsylvania
| – | -$1K | -196 | Closed |
|
|
IA
10
IFP Advisors
Tampa,
Florida
| – | +$12 | +5 | New |
|
RSLS Hedge Fund Activity: Q4 2018 in Review
2 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in ReShape Lifesciences Inc. Common Stock (RSLS) for Q4 2018, worth a combined $187K — up 23% from $152K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RSLS and 1 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $1.72M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $101K sold.
- 2 institutional investors held ReShape Lifesciences Inc. Common Stock (RSLS) as of Q4 2018, down from 15 in Q3 2018.
- Funds reported $187K of ReShape Lifesciences Inc. Common Stock stock for Q4 2018, up 23% quarter-over-quarter.
- 1 fund opened new ReShape Lifesciences Inc. Common Stock positions in Q4 2018 and 14 closed out, a net change of -13 holders.
- The largest ReShape Lifesciences Inc. Common Stock buyer in Q4 2018 was Sabby Management, an estimated $1.72M added.
- The largest ReShape Lifesciences Inc. Common Stock seller in Q4 2018 was Renaissance Technologies, an estimated $101K sold.
Based on aggregated 13F filings for Q4 2018.